Wockhardt Ltd

BSE: WOCKPHARMA532300ISIN INE049B01025

Healthcare
Pharmaceuticals
BSE 500

Share price

₹1,899.80+31.45 (+1.68%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹2,420.00
52W low: ₹1,086.80
Off 52W high: -21.50%
1M return: -7.85%
3M return: -5.76%
6M return: +10.44%
1Y return: +39.18%
20D avg volume: 49,017
50 DMA: ₹2,024.60
200 DMA: ₹1,711.06

Key ratios Consolidated

Market cap: ₹30,869 Cr
Current price: ₹1,899.80
52W high / low: ₹2,420.00 / ₹1,086.80
Face value: ₹5.00
P/E: 76.22
P/B: 5.97
EPS (TTM): ₹24.92
Book value / share: ₹318.40
ROE: —
ROCE: 6.40%
Operating margin: —
Net margin: —
Debt / equity: 0.40
Net debt: ₹1,908 Cr
Interest cover: 2.12
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 98.7 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	969.00	929.00	965.00	888.00	782.00	738.00	743.00	721.00	809.00	739.00	700.00	701.00
	11.00	31.00	45.00	25.00	21.00	20.00	15.00	8.00	9.00	30.00	54.00	8.00
	980.00	960.00	1,010	913.00	803.00	758.00	758.00	729.00	818.00	769.00	754.00	709.00
	907.00	844.00	843.00	836.00	712.00	770.00	780.00	708.00	827.00	775.00	934.00	796.00
	243.00	233.00	177.00	170.00	159.00	168.00	159.00	121.00	182.00	150.00	144.00	160.00
	123.00	109.00	156.00	161.00	129.00	140.00	148.00	122.00	150.00	153.00	154.00	150.00
	201.00	203.00	187.00	181.00	186.00	171.00	166.00	164.00	161.00	160.00	157.00	152.00
	56.00	52.00	50.00	60.00	55.00	48.00	48.00	60.00	73.00	73.00	73.00	77.00
	55.00	55.00	53.00	65.00	53.00	56.00	53.00	55.00	55.00	54.00	58.00	55.00
	254.00	214.00	235.00	213.00	185.00	231.00	253.00	—	—	174.00	229.00	—
	73.00	116.00	167.00	77.00	91.00	-12.00	-22.00	21.00	-9.00	-6.00	-180.00	-87.00
	0.00	0.00	22.00	-10.00	0.00	-97.00	0.00	0.00	0.00	0.00	0.00	0.00
	73.00	116.00	189.00	67.00	91.00	-109.00	-22.00	21.00	-9.00	-6.00	-180.00	-87.00
	0.00	9.00	25.00	6.00	9.00	-1.00	23.00	1.00	7.00	10.00	3.00	1.00
	73.00	107.00	164.00	61.00	82.00	-108.00	-45.00	20.00	-16.00	-16.00	-177.00	-86.00
	4.85	6.55	10.23	3.61	4.81	-5.53	-1.57	0.91	-1.47	-0.95	-11.64	-5.75
Key metrics
	184.00	223.00	292.00	192.00	199.00	-5.00	79.00	136.00	119.00	121.00	-49.00	45.00
	19.00%	24.00%	30.30%	21.60%	25.40%	-0.70%	10.60%	18.90%	14.70%	16.40%	-7.00%	6.40%
	7.50%	11.50%	17.00%	6.90%	10.50%	-14.60%	-6.10%	2.80%	-2.00%	-2.20%	-25.30%	-12.30%
	1.80%	—	3.40%	—	2.10%	—	0.40%	—	—	—	—	—
	23.90%	25.90%	29.90%	23.20%	-3.30%	-0.10%	6.10%	2.90%	—	—	—	—
	-11.00%	199.10%	464.40%	205.00%	612.50%	-575.00%	74.60%	123.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	3,751	3,373	3,012	2,798	2,651	3,230	2,708	2,844	4,158	3,937	4,015
	112.00	111.00	62.00	83.00	122.00	20.00	132.27	38.81	21.02	120.23	114.25
	3,863	3,484	3,074	2,881	2,773	3,250	2,841	2,883	4,179	4,057	4,129
	3,430	3,161	3,090	3,287	3,103	3,478	3,266	3,225	4,480	4,340	4,376
	823.00	674.00	612.00	620.00	518.00	612.00	682.43	621.72	854.18	867.53	891.90
	549.00	586.00	573.00	559.00	509.00	568.00	579.90	507.70	919.09	751.47	796.04
	772.00	725.00	651.00	629.00	637.00	749.00	762.95	743.33	936.90	937.06	966.51
	218.00	213.00	254.00	305.00	302.00	299.00	249.08	275.74	264.89	255.49	225.27
	228.00	227.00	217.00	223.00	251.00	247.00	246.02	224.14	166.04	—	—
	916.00	864.00	836.00	834.00	802.00	916.00	870.43	799.45	1,272	1,258	1,360
	433.00	323.00	-16.00	-406.00	-330.00	-228.00	-425.86	-342.04	-300.32	-282.96	-247.15
	12.00	-85.00	0.00	-14.00	-294.00	-183.00	-142.48	0.00	0.00	-358.19	0.00
	445.00	238.00	-16.00	-420.00	-624.00	-411.00	-568.34	-342.04	-300.32	-641.15	-247.15
	40.00	39.00	41.00	52.00	3.00	132.00	271.61	204.09	83.66	25.70	21.11
	405.00	199.00	-57.00	-472.00	-621.00	-279.00	688.60	-43.39	-216.66	-666.85	-226.04
	25.24	13.12	-3.02	-32.05	-38.79	-20.24	-27.02	-14.79	-17.58	—	-17.71
Key metrics
	891.00	678.00	455.00	108.00	-71.00	135.00	-73.24	157.84	130.61	-385.66	-21.88
	23.75%	20.10%	15.10%	3.90%	-2.70%	4.20%	-2.70%	5.50%	3.10%	-9.80%	-0.50%
	10.80%	5.90%	-1.90%	-16.90%	-23.40%	-8.60%	25.40%	-1.50%	-5.20%	-16.90%	-5.60%
	—	6.40%	3.90%	—	—	—	—	—	—	—	—
	25.70%	12.00%	7.60%	5.50%	-17.90%	19.30%	-4.80%	-31.60%	5.60%	-1.90%	—
	—	449.10%	87.90%	24.00%	-122.60%	-140.50%	1,687.00%	80.00%	67.50%	-195.00%	—
	—	254.00	-116.00	—	—	—	—	—	—	—	—
	—	1.96	0.39	—	—	—	—	—	—	—	—
	—	0.40	0.40	—	—	—	—	—	—	—	—
	—	1,908	1,747	—	—	—	—	—	—	—	—
	—	98.7	96.3	—	—	—	—	—	—	—	—
Balance sheet
	—	8,615	8,135	—	—	—	—	—	—	—	—
	—	2,606	2,465	—	—	—	—	—	—	—	—
	—	217.00	112.00	—	—	—	—	—	—	—	—
	—	588.00	661.00	—	—	—	—	—	—	—	—
	—	887.00	725.00	—	—	—	—	—	—	—	—
	—	418.00	412.00	—	—	—	—	—	—	—	—
	—	1,618	1,718	—	—	—	—	—	—	—	—
	—	563.00	592.00	—	—	—	—	—	—	—	—
	—	1,622	2,042	—	—	—	—	—	—	—	—
	—	2,125	1,859	—	—	—	—	—	—	—	—
	—	607.00	648.00	—	—	—	—	—	—	—	—
	—	1,518	1,211	—	—	—	—	—	—	—	—
	—	5,281	4,657	—	—	—	—	—	—	—	—
Cash flow
	—	390.00	-22.00	—	—	—	—	—	—	—	—
	—	-241.00	-783.00	—	—	—	—	—	—	—	—
	—	-54.00	409.00	—	—	—	—	—	—	—	—
	—	136.00	94.00	—	—	—	—	—	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	580.00	561.00	516.00	430.00	380.00	413.00	355.00	325.00	370.00	352.00	355.00	288.00
	21.00	33.00	55.00	27.00	30.00	25.00	14.00	6.00	11.00	27.00	24.00	5.00
	601.00	594.00	571.00	457.00	410.00	438.00	369.00	331.00	381.00	379.00	379.00	293.00
	501.00	487.00	439.00	419.00	356.00	369.00	329.00	353.00	417.00	373.00	505.00	367.00
	135.00	106.00	79.00	81.00	75.00	74.00	76.00	64.00	88.00	82.00	92.00	80.00
	54.00	57.00	40.00	67.00	51.00	39.00	44.00	46.00	51.00	31.00	41.00	45.00
	96.00	85.00	79.00	78.00	88.00	68.00	64.00	71.00	65.00	62.00	62.00	59.00
	48.00	43.00	41.00	50.00	44.00	41.00	40.00	48.00	53.00	58.00	59.00	61.00
	47.00	41.00	43.00	52.00	45.00	46.00	40.00	42.00	43.00	43.00	45.00	43.00
	168.00	154.92	156.00	129.00	108.00	101.05	100.00	104.00	118.00	82.00	125.00	86.00
	100.00	107.00	132.00	38.00	54.00	69.00	40.00	-22.00	-36.00	6.00	-126.00	-74.00
	0.00	0.00	35.00	-10.00	0.00	0.00	0.00	—	—	—	—	—
	100.00	107.00	167.00	28.00	54.00	69.00	40.00	-22.00	-36.00	6.00	-126.00	-74.00
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	100.00	107.00	167.00	28.00	54.00	69.00	40.00	-22.00	-36.00	6.00	-126.00	-74.00
	6.15	6.62	10.29	1.73	3.26	4.25	2.47	-1.40	-2.34	0.39	-8.71	-5.14
Key metrics
	195.00	191.00	251.00	130.00	143.00	156.00	120.00	68.00	60.00	107.00	-22.00	30.00
	33.60%	34.00%	48.60%	30.20%	37.60%	37.80%	33.80%	20.90%	16.20%	30.40%	-6.20%	10.40%
	17.20%	19.10%	32.40%	6.50%	14.20%	16.70%	11.30%	-6.80%	-9.70%	1.70%	-35.50%	-25.70%
	3.20%	—	4.60%	—	2.20%	—	2.00%	—	—	—	—	—
	52.60%	35.80%	45.40%	32.30%	2.70%	17.30%	0.00%	12.80%	—	—	—	—
	85.20%	55.10%	317.50%	227.30%	250.00%	1,050.00%	131.70%	70.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	2,087	1,739	1,402	1,154	1,072	1,372	987.26	890.06	2,150	2,477	2,298
	136.00	137.00	55.00	41.00	67.00	38.00	40.73	43.02	31.00	56.85	248.31
	2,223	1,876	1,457	1,195	1,139	1,410	1,028	933.08	2,181	2,534	2,546
	1,846	1,584	1,469	1,603	1,417	1,594	1,509	1,417	2,356	2,430	2,427
	401.00	309.00	310.00	285.00	200.00	283.00	253.10	236.70	464.73	457.12	535.22
	218.00	198.00	172.00	162.00	171.00	191.00	164.97	85.20	402.48	—	428.66
	338.00	313.00	262.00	247.00	240.00	261.00	293.36	325.46	482.20	—	523.22
	182.00	176.00	199.00	237.00	229.00	273.00	200.24	220.17	170.63	169.58	168.72
	183.00	186.00	168.00	176.00	186.00	171.00	184.08	173.39	121.91	—	—
	607.92	494.00	404.00	403.00	361.00	413.00	386.61	427.25	713.20	667.09	691.29
	377.00	292.00	-12.00	-408.00	-278.00	-184.00	-481.29	-483.68	-175.43	103.92	118.78
	25.00	25.00	0.00	-14.00	-235.00	—	-142.48	—	—	—	—
	402.00	317.00	-12.00	-422.00	-513.00	-184.00	-623.77	-483.68	-175.43	103.92	118.78
	0.00	0.00	0.00	—	47.00	44.00	231.73	158.00	93.54	35.26	18.34
	402.00	317.00	-12.00	-422.00	-466.00	-140.00	593.29	-231.12	-81.89	68.66	137.12
	24.79	19.54	-0.76	-29.27	-32.40	-11.62	-35.40	-29.42	-7.40	—	12.40
Key metrics
	767.00	679.00	355.00	-9.00	-98.00	260.00	-239.45	-90.12	117.11	273.50	287.50
	36.75%	39.00%	25.30%	-0.80%	-9.10%	19.00%	-24.30%	-10.10%	5.40%	11.00%	12.50%
	19.26%	18.20%	-0.90%	-36.60%	-43.50%	-10.20%	60.10%	-26.00%	-3.80%	2.80%	6.00%
	—	10.90%	4.80%	—	—	—	—	—	—	—	—
	41.68%	24.00%	21.50%	7.60%	-21.90%	39.00%	10.90%	-58.60%	-13.20%	7.80%	—
	185.11%	2,741.70%	97.20%	9.40%	-232.90%	-123.60%	356.70%	-182.20%	-219.30%	-49.90%	—
	—	155.00	-55.00	—	—	—	—	—	—	—	—
	—	0.76	1.17	—	—	—	—	—	—	—	—
	—	0.57	0.55	—	—	—	—	—	—	—	—
	—	1,669	1,492	—	—	—	—	—	—	—	—
	—	183.9	146.3	—	—	—	—	—	—	—	—
Balance sheet
	—	5,935	5,408	—	—	—	—	—	—	—	—
	—	2,290	1,990	—	—	—	—	—	—	—	—
	—	76.00	35.00	—	—	—	—	—	—	—	—
	—	846.00	612.00	—	—	—	—	—	—	—	—
	—	533.00	426.00	—	—	—	—	—	—	—	—
	—	—	332.00	—	—	—	—	—	—	—	—
	—	1,128	1,240	—	—	—	—	—	—	—	—
	—	503.00	476.00	—	—	—	—	—	—	—	—
	—	1,426	1,483	—	—	—	—	—	—	—	—
	—	1,745	1,527	—	—	—	—	—	—	—	—
	—	501.00	590.00	—	—	—	—	—	—	—	—
	—	1,244	937.00	—	—	—	—	—	—	—	—
	—	3,084	2,763	—	—	—	—	—	—	—	—
Cash flow
	—	241.00	-14.00	—	—	—	—	—	—	—	—
	—	-193.00	-900.00	—	—	—	—	—	—	—	—
	—	-7.00	486.00	—	—	—	—	—	—	—	—
	—	86.00	41.00	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +17.50%
Sales CAGR 5Y: +11.99%
Profit CAGR 3Y: —
Profit CAGR 5Y: -11.78%
Sales YoY (TTM): +41.68%
Profit YoY (TTM): +185.11%

Consolidated

Sales CAGR 3Y: +8.36%
Sales CAGR 5Y: +4.49%
Profit CAGR 3Y: —
Profit CAGR 5Y: -21.99%
Sales YoY (TTM): +25.70%
Profit YoY (TTM): +894.12%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 49.33%

Quarter	September 2026	June 2026
Promoter %	49.33%	49.09%

Holder	Type	Holding	Previous	Change
Themisto Trustee Company Private Limited	Promoter	40.47%	40.23%	+0.24%
Pasithee Trustee Company Private Limited	Promoter Group	3.12%	3.12%	0.00%
Ananke Trustee Company Private Limited	Promoter Group	2.52%	2.52%	0.00%
Callirhoe Trustee Company Private Limited	Promoter Group	2.50%	2.50%	0.00%
Tata Mutual Fund - Tata Small Cap Fund	Public	2.03%	2.03%	0.00%
Rekha Jhunjhunwala	Public	1.75%	1.75%	0.00%
Sbi Life Insurance Co. Ltd	Public	1.64%	—	—
Hsbc Mutual Fund - Hsbc Small Cap Fund	Public	1.17%	1.30%	-0.13%
Habil F Khorakiwala	Promoter	0.37%	0.37%	0.00%
Murtaza Habil Khorakiwala	Promoter Group	0.18%	0.18%	0.00%
Huzaifa Habil Khorakiwala	Promoter Group	0.17%	0.17%	0.00%
Khorakiwala Holdings and Investments Private Limited	Promoter Group	0.00%	0.00%	0.00%
Muayyad H Khorakiwala	Promoter Group	0.00%	0.00%	0.00%
Miqdad H Khorakiwala	Promoter Group	0.00%	0.00%	0.00%
Zahabiya Khorakiwala	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Please refer the attachment.2 Nov 2026 · Company Update / Monitoring Agency Report
Appointment of Mr. Sumit Garg as Chief Digital & Information Officer as Senior Management Personnel of the Company.2 Nov 2026 · Company Update / Change in Management
Please refer the attachment.2 Nov 2026 · Company Update / Press Release / Media Release
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of directors at its meeting held today, i.e. 2nd November, 2026, inter-alia, ....2 Nov 2026 · Result / Financial Results
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company, at its meeting ....2 Nov 2026 · Board Meeting / Outcome of Board Meeting
We wish to inform that Share Allotment Committee of Board of Directors of the Company has allotted 20000 equity shares of face value of Rs 5 each on 27th October, 2026 pursuant to exercise ....27 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI ....27 Oct 2026 · Board Meeting / Board Meeting
Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations, 2015, we enclose herewith a copy of newspaper advertisement regarding the opening of special ....24 Oct 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find attached the Certificate received from MUFG Intime India Private Limited, Registrar and ....9 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Trading Window for dealing in the equity shares of the Company will be closed from 1st October, 2026 until 48 hours after the declaration of Unaudited financial results for quarter ....25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to Regulation 30 (read with Part A of Schedule III) of SEBI (LODR) Regulations 2015, we wish to inform you that the Company is in receipt of an Adjudication Order passed by Commissioner ....25 Aug 2026 · Others
Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations, 2015, we enclose herewith a copy of newspaper advertisement published today i.e. 25th August, ....25 Aug 2026 · Company Update / Newspaper Publication
Please find enclosed herewith Scrutinizer''s Report on the combined voting results of remote e-voting and e-voting during the 27th AGM of the Company10 Aug 2026 · AGM/EGM / AGM
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (LODR) Regulations, 2015, the Proceedings of the 27th AGM of the Company10 Aug 2026 · AGM/EGM / AGM
Pursuant to Regulation 32(6) of SEBI (LODR) Regulations 2015, read with Regulation 173A of SEBI (ICDR) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilisation ....10 Aug 2026 · Company Update / Monitoring Agency Report
Please find enclosed Press Release - "Wockhardt Antibiotic Academy, an initiative for Patient-Centric Scientific Dialogue to Tackle Multidrug Resistance".10 Aug 2026 · Company Update / Press Release / Media Release
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 202610 Aug 2026 · Company Update / Press Release / Media Release
Pursuant to Regulation 30 of SEBI Listing Regulations, the Board of Directors at its meeting held today i.e. 10th August, 2026, has approved the Unaudited Financial Results (Standalone ....10 Aug 2026 · Result / Financial Results
Pursuant to Regulation 30 of SEBI Listing Regulations, Board of Directors at its meeting held today i.e 10th August, 2026 has approved the Unaudited Financial Results (Standalone and Consolidated) ....10 Aug 2026 · Board Meeting / Outcome of Board Meeting
Pursuant to Regulation 30 read with schedule III (Part A Para A) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find ....7 Aug 2026 · Company Update / Newspaper Publication
Please find enclosed herewith the addendum to the Notice of the 27th Annual General Meeting of the Company scheduled to be held on Monday, 10th August, 2026.5 Aug 2026 · AGM/EGM / AGM
Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI ....4 Aug 2026 · Board Meeting / Board Meeting
Please find enclosed the copies of Newspaper Advertisement published today i.e. 18th July, 2026 in respect to the information regarding the 27th Annual General Meeting (''AGM'') of the ....18 Jul 2026 · Company Update / Newspaper Publication
Please find enclosed the Business Responsibility and Sustainability Report and Independent Assurance Statement on BRSR Core parameters issued by SGS India Private Limited for the Financial ....17 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Please find enclosed herewith the Annual Report of the Company for the Financial Year 2025-26.17 Jul 2026 · Others / Reg. 34 (1) Annual Report
Please find enclosed herewith the Notice of 27th Annual General Meeting of Wockhardt Limited scheduled to be held on Monday, 10th August, 2026, at 3:30 p.m. through Video Conferencing/ ....17 Jul 2026 · AGM/EGM / AGM
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed the Certificate received from MUFG Intime India Private Limited, Registrar and ....10 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 30 read with Schedule III (Part A Para A) of SEBI Listing Regulations, please find enclosed herewith newspaper extracts of public notice relating to 27th AGM of the ....3 Jul 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed herewith newspaper advertisement published today i.e. 26th June, ....26 Jun 2026 · Company Update / Newspaper Publication
This is to inform that pursuant to Company''s ''Code of Conduct for regulating, monitoring and reporting of trading by designated persons'' (''the Code''), the Trading Window for dealing ....25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to Regulation 30 of the Securities and Exchange Board of India (LODR) Regulations, 2015, as amended and in continuation to our letter bearing reference no. Ref.no. WOCK/SEC/SE/2025-26/015 ....11 Jun 2026 · Company Update / Earnings Call Transcript
Pursuant to Regulation 30 of SEBI (LODR), Regulations, 2015, please find enclosed herewith copy of the Investor Presentation to be made at the Investor Meeting scheduled to be held on 4th June, 2026.4 Jun 2026 · Company Update / Investor Presentation
Pursuant to Regulation 30 of the SEBI(LODR) Regulations, 2015, we wish to inform you that the Company will hold an Investor Meet on Thursday, 4th June, 2026 at 4:00 pm IST.1 Jun 2026 · Company Update / Analyst / Investor Meet
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release - "Wockhardt Receives U.S. FDA Approval for ZAYNICH (cefepime and zidebactam), a Novel Intravenous Antibiotic ....30 May 2026 · Company Update / Press Release / Media Release
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Annual Secretarial Compliance Report for the year ended 31st March, 202628 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release - "Indian drug regulator grants marketing authorization to Wockhardt''s breakthrough antibiotic , ZAYNICH ....28 May 2026 · Company Update / Press Release / Media Release
ICRA Limited has upgraded the Credit Rating as given below: Long Term- Fund Based- Term Loan- Present Rating- A- (Stable); Previous Rating- BBB (Positive) Long Term/ Short Term- Fund ....21 May 2026 · Company Update / Credit Rating
Monitoring Agency Report for quarter ended 31st March, 2026.4 May 2026 · Company Update / Monitoring Agency Report
Change in Senior Management Personnel.4 May 2026 · Company Update / Change in Management
Submission pursuant to Regulation 30 (LODR)Regulations, 2015- Press Release4 May 2026 · Company Update / Press Release / Media Release

Board meetings

2 Nov 2026 Board Meeting - Financial Results
10 Aug 2026 Board Meeting - Financial Results